Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALCNASDAQ:CYTHNASDAQ:RLMDNASDAQ:RNAZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$1.63-1.2%$1.73$1.43▼$5.97$22.77M1.2645,600 shs23,914 shsCYTHCyclo Therapeutics$0.72$0.72$0.55▼$1.45$23.72M-0.57527,459 shsN/ARLMDRelmada Therapeutics$0.54-8.9%$0.56$0.24▼$4.47$17.89M0.65959,674 shs371,594 shsRNAZTransCode Therapeutics$7.90+1.3%$8.57$6.15▼$1,034.88$6.58M1.33102,906 shs2,491 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+7.14%-2.37%-8.33%-17.09%-68.15%CYTHCyclo Therapeutics0.00%0.00%0.00%+3.39%-38.93%RLMDRelmada Therapeutics-2.97%-15.92%-7.43%+92.86%-80.27%RNAZTransCode Therapeutics+3.87%+14.22%+11.76%-52.85%-99.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica2.886 of 5 stars3.55.00.00.00.63.30.0CYTHCyclo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARLMDRelmada Therapeutics4.7509 of 5 stars3.15.00.04.42.24.21.3RNAZTransCode Therapeutics1.5189 of 5 stars3.53.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$18.001,004.29% UpsideCYTHCyclo Therapeutics 2.33Hold$0.9531.83% UpsideRLMDRelmada Therapeutics 2.25Hold$5.00827.64% UpsideRNAZTransCode Therapeutics 3.00Buy$280.003,446.55% UpsideCurrent Analyst Ratings BreakdownLatest RNAZ, CALC, CYTH, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/16/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$560.00 ➝ $280.004/1/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$1.07 per shareN/ACYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ARNAZTransCode TherapeuticsN/AN/AN/AN/A($54.96) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$13.70M-$1.56N/AN/AN/AN/A-171.81%-100.43%8/11/2025 (Estimated)CYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/ARLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)RNAZTransCode Therapeutics-$16.75MN/A0.00N/AN/AN/A-578.88%-222.61%N/ALatest RNAZ, CALC, CYTH, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q4 2024RNAZTransCode Therapeutics-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A5/14/2025Q1 2025CALCCalciMedica-$0.43-$0.36+$0.07-$0.36N/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/A3/27/2025Q4 2024CALCCalciMedica-$0.48-$0.34+$0.14-$0.34N/AN/A3/27/2025Q4 2024RLMDRelmada Therapeutics-$0.70-$0.62+$0.08-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedica0.795.665.66CYTHCyclo TherapeuticsN/A0.170.16RLMDRelmada TherapeuticsN/A5.295.29RNAZTransCode TherapeuticsN/A5.205.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ACYTHCyclo Therapeutics68.55%RLMDRelmada Therapeutics45.24%RNAZTransCode TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%CYTHCyclo Therapeutics29.78%RLMDRelmada Therapeutics20.70%RNAZTransCode Therapeutics0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.97 million8.17 millionNo DataCYTHCyclo Therapeutics932.92 million23.12 millionNo DataRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableRNAZTransCode Therapeutics9833,000832,000Not OptionableRNAZ, CALC, CYTH, and RLMD HeadlinesRecent News About These CompaniesTransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory BoardMay 28, 2025 | prnewswire.comTransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities ReportedMay 8, 2025 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitMay 6, 2025 | finanznachrichten.deTransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitMay 5, 2025 | prnewswire.comTransCode Therapeutics approves reverse stock split to meet Nasdaq rulesMay 4, 2025 | investing.comTransCode reports progress in metastatic cancer trialMay 3, 2025 | uk.investing.comTransCode Therapeutics Announces 1-for-28 Reverse Stock SplitMay 2, 2025 | prnewswire.comIBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138May 2, 2025 | finance.yahoo.comTransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138May 2, 2025 | financial-news.co.ukTransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic CancerMay 1, 2025 | prnewswire.comTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special MeetingApril 21, 2025 | prnewswire.comAll You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to BuyApril 18, 2025 | zacks.comTranscode Therapeutics price target lowered to $10 from $20 at H.C. WainwrightApril 17, 2025 | markets.businessinsider.comTranscode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trialMarch 28, 2025 | markets.businessinsider.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138March 28, 2025 | finanznachrichten.deTransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138March 27, 2025 | prnewswire.comTransCode Therapeutics, Inc. Announces Closing of Registered Direct OfferingMarch 25, 2025 | prnewswire.comTranscode to sell 10.25M shares at 98c per share in registered direct offeringMarch 25, 2025 | markets.businessinsider.comTransCode Therapeutics stock slides after announces to raise $10M securities offeringMarch 24, 2025 | msn.comTransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 23, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNAZ, CALC, CYTH, and RLMD Company DescriptionsCalciMedica NASDAQ:CALC$1.63 -0.02 (-1.21%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Cyclo Therapeutics NASDAQ:CYTH$0.72 0.00 (0.00%) As of 03/26/2025Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.Relmada Therapeutics NASDAQ:RLMD$0.54 -0.05 (-8.94%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.TransCode Therapeutics NASDAQ:RNAZ$7.90 +0.11 (+1.35%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
